Vega Therapeutics launches and unveils its first-in-class antibody therapy for von Willebrand diseas
With $40 million in financing to date, company has advanced lead drug candidate, VGA039, to clinical stage to treat von Willebrand disease (VWD)Oral presentation at ASH will feature preclinical data of VGA039, a monoclonal antibody with potential to be a universal hemostatic therapy for bleeding disordersCompany has...
Source: pharmiweb.com